SL-172154 SIRPα-Fc-CD40L
Overview
We are conducting multiple Phase 1 clinical trials evaluating the administration of SL-172154 in both solid tumors and hematologic malignancies.
In solid tumors, we are evaluating SL-172154 in a Phase 1B combination dose-escalation and dose-expansion clinical trial in platinum-resistant ovarian cancer in combination with liposomal doxorubicin. In addition to our combination strategy of SL-172154 in combination with liposomal doxorubicin, we are evaluating SL-172154 in a Phase 1B combination dose-escalation and dose-expansion clinical trial in platinum-resistant ovarian cancer in combination with mirvetuximab soravtansine.
As for our hematologic program, we are conducting a Phase 1A/B clinical trial for SL-172154 in patients with AML and HR-MDS. This ongoing Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, antitumor activity, and pharmacodynamic effects of SL-172154, as both monotherapy and in combination. In AML, we plan to evaluate SL-172154 in combination with both azacitidine and venetoclax. In both HR-MDS and TP53 mutant AML, we plan to evaluate SL-172154 in combination with azacitidine. We are conducting the Phase 1B dose-escalation portion of this trial of SL-172154 in combination with azacitidine in a parallel staggered manner.
SL-172154 Clinical Trial Information
Healthcare Professionals: To learn more about Shattuck’s trials, email clinicaltrials@shattucklabs.com.
Patients and Caregivers: Talk to your doctor if you are interested in learning more about Shattuck clinical trials.
Investigational: These molecules and their uses are investigational and have not been approved for use anywhere in the world.
